{"id":56498,"date":"2024-06-22T00:05:08","date_gmt":"2024-06-22T00:05:08","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/06\/22\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/"},"modified":"2024-06-22T00:05:08","modified_gmt":"2024-06-22T00:05:08","slug":"sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/","title":{"rendered":"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference"},"content":{"rendered":"<div>\n<ul type=\"disc\">\n<li><i>A Phase 1 study of oral\u00a0ecnoglutide (<b>1871-LB<\/b>) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekly subcutaneous GLP-1 analogs for weight loss.<\/i><\/li>\n<li><i>In a Phase 3 study in participants with type 2 diabetes (T2DM) (<b>742-P, 793-P<\/b>), weekly subcutaneous ecnoglutide resulted in robust HbA1c declines of up to -2.43% from baseline after 24 weeks of treatment, with up to 35.2% of participants reaching normoglycemia (HbA1c &lt;5.7%) and 43.7% with weight reductions \u22655%.<\/i><\/li>\n<li><i>Novel\u00a0amylin analogs (<b>788-P, 789-P<\/b>) were identified that showed potent in vitro activity. In preclinical models, combination of amylin analogs with ecnoglutide demonstrated a synergistic effect on body weight reduction, with improved efficacy compared to combination of cagrilintide and semaglutide. Moreover, a novel amylin development candidate was identified that is stable at neutral pH, providing the opportunity to co-formulate with ecnoglutide <\/i>or other GLP-1 analogs <i>to improve ease of use for patients and reduce costs.<\/i><\/li>\n<\/ul>\n<p><span class=\"xn-location\">HANGZHOU, China<\/span> and <span class=\"xn-location\">SAN FRANCISCO<\/span>, <span class=\"xn-chron\">June 22, 2024<\/span> \/PRNewswire\/ &#8212; Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide (XW003) in T2DM patients and from a Phase 1 study for oral ecnoglutide (XW004) in healthy and healthy obese participants, as well as preclinical data for novel amylin analog programs, at the American Diabetes Association (ADA) 84th Annual Conference.<\/p>\n<p>Five posters, including one late-breaking poster, will be presented. The ADA conference is being held in <span class=\"xn-location\">Orlando, FL<\/span> <span class=\"xn-chron\">June 21-24<\/span>, 2024.\u00a0<\/p>\n<p><b>Late Breaking Poster Presentation (1871-LB): <span class=\"xn-chron\">Saturday June 22<\/span>, <span class=\"xn-chron\">12:30 PM &#8211; 1:30 PM<\/span><br \/><\/b><i>&#8220;Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide&#8221;<\/i><\/p>\n<p><b>Poster Presentation (742-P): <span class=\"xn-chron\">Sunday June 23<\/span>, <span class=\"xn-chron\">12:30 PM &#8211; 1:30 PM<\/span><br \/><\/b><i>&#8220;A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes&#8221;<\/i><\/p>\n<p><b>Poster Presentation (793-P): <span class=\"xn-chron\">Sunday June 23<\/span>, <span class=\"xn-chron\">12:30 PM &#8211; 1:30 PM<\/span><br \/><\/b><i>&#8220;Biased GLP-1 analog ecnoglutide (XW003) has improved efficacy relative to unbiased peptides&#8221;<\/i><\/p>\n<p><b>Poster Presentation (789-P): <span class=\"xn-chron\">Sunday June 23<\/span>, <span class=\"xn-chron\">12:30 PM &#8211; 1:30 PM<\/span><br \/><\/b><i>&#8220;Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control&#8221;<\/i><\/p>\n<p><b>Poster Presentation (788-P): <span class=\"xn-chron\">Sunday June 23<\/span>, <span class=\"xn-chron\">12:30 PM &#8211; 1:30 PM<\/span><br \/><\/b><i>&#8220;Synergistic Body Weight Reduction of GLP-1 Analog Ecnoglutide and Amylin Analogs in Preclinical Animal Models&#8221;<\/i><\/p>\n<p><b>About ecnoglutide <\/b><\/p>\n<p>Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for MASH.\u00a0 Ecnoglutide is a novel, biased, long-acting GLP-1 peptide analog optimized for improved biological activity, cost-effective manufacturing, and once weekly subcutaneous dosing. Ecnoglutide has demonstrated treatment benefits for patients with type 2 diabetes and obesity and is safe and well tolerated in Phase 1 through Phase 3 clinical studies.<\/p>\n<p><b>About Sciwind <\/b><\/p>\n<p>Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates, including the long-acting GLP-1 peptide analog XW003 (Phase 3), oral GLP-1 peptide analog XW004 (Phase 1), an oral small molecule GLP-1 receptor agonist XW014 (Phase 1), and novel amylin analogs (preclinical). Sciwind\u00a0has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information, visit <u><a href=\"https:\/\/www.sciwindbio.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.sciwindbio.com<\/a><\/u>.\u00a0<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>A Phase 1 study of oral\u00a0ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 weeks of dosing). Improved oral bioavailability enables a 15 to 30 mg daily dose of oral ecnoglutide to match or exceed the plasma exposure of weekly subcutaneous GLP-1 analogs [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-56498","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference\" \/>\n<meta property=\"og:description\" content=\"A Phase 1 study of oral\u00a0ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 week\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-22T00:05:08+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference\",\"datePublished\":\"2024-06-22T00:05:08+00:00\",\"dateModified\":\"2024-06-22T00:05:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/\"},\"wordCount\":575,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/\",\"name\":\"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-06-22T00:05:08+00:00\",\"dateModified\":\"2024-06-22T00:05:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/","og_locale":"en_US","og_type":"article","og_title":"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference","og_description":"A Phase 1 study of oral\u00a0ecnoglutide (1871-LB) showed it to be safe and well tolerated and result in pronounced weight loss (up to -6.76% after 6 week","og_url":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-06-22T00:05:08+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference","datePublished":"2024-06-22T00:05:08+00:00","dateModified":"2024-06-22T00:05:08+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/"},"wordCount":575,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/","url":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/","name":"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-06-22T00:05:08+00:00","dateModified":"2024-06-22T00:05:08+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/sciwind-biosciences-to-highlight-positive-results-for-injectable-ecnoglutide-phase-3-oral-ecnoglutide-phase-1-and-novel-amylin-analogs-at-the-american-diabetes-association-ada-84th-annual-conf\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Sciwind Biosciences to Highlight Positive Results for Injectable Ecnoglutide (Phase 3), Oral Ecnoglutide (Phase 1), and Novel Amylin Analogs at the American Diabetes Association (ADA) 84th Annual Conference"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/56498","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=56498"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/56498\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=56498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=56498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=56498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}